Virtus Advisers LLC Acquires New Holdings in ANI Pharmaceuticals, Inc. $ANIP

Virtus Advisers LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, HoldingsChannel reports. The firm bought 14,294 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,183,000.

Several other hedge funds have also recently bought and sold shares of ANIP. KBC Group NV bought a new position in ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the first quarter worth $28,000. Hantz Financial Services Inc. increased its position in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $48,000. Finally, State of Wyoming acquired a new stake in shares of ANI Pharmaceuticals during the second quarter worth $50,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Canaccord Genuity Group dropped their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Guggenheim reduced their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.83.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $77.32 on Friday. ANI Pharmaceuticals, Inc. has a 12 month low of $70.15 and a 12 month high of $99.50. The company’s fifty day simple moving average is $80.48 and its 200-day simple moving average is $78.91. The firm has a market cap of $1.78 billion, a PE ratio of 16.66 and a beta of 0.44. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. During the same period in the previous year, the firm posted $1.80 EPS. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Stephen P. Carey sold 3,313 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total transaction of $284,918.00. Following the sale, the chief financial officer owned 177,543 shares in the company, valued at $15,268,698. This represents a 1.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the sale, the director directly owned 38,878 shares of the company’s stock, valued at approximately $3,144,452.64. The trade was a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 18,987 shares of company stock valued at $1,546,405. 8.10% of the stock is currently owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.